Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.
Open accessAbstract
OBJECTIVE: As psychopathology and social functioning can worsen with repeated psychotic episodes in schizophrenia, relapse prevention is critical. Because high nonadherence rates limit the efficacy of pharmacotherapy, the use of long-acting injectable (LAI) antipsychotics is considered an important treatment option. To date, many studies comparing LAIs and oral antipsychotics have been conducted; however, the results are mixed, and careful interpretation of the data is required. STUDY DESIGN AND SETTING: Selective review of existing literature regarding LAIs. We especially focused the discussion on the impact of the design of studies with different approaches comparing LAIs and oral antipsychotics in preventing relapse. RESULT: The results were diverse and were influenced by the design used, that is, randomized controlled trials (RCTs) showed LAIs and oral antipsychotics to have similar effects, whereas mirror-image and some large cohort studies showed LAIs to be superior to oral antipsychotics. CONCLUSION: Divergent results from studies using different methodologies create a dilemma for comparative effectiveness research, and LAI studies may serve as an example of a situation in which a conventional RCT is not the gold standard. Traditional RCTs generally increase adherence compared with clinical practice and, therefore, might not be well suited to detect differences between LAIs and oral medications, because any increase in adherence affects patients on oral medications more than those on LAIs and thus leads to an underestimation of any potential difference in effectiveness. A possible solution would be the implementation of a true effectiveness trial in which post-randomization involvement would be kept to a minimum to better reflect routine practice.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Although RCTs can provide the highest level of evidence, this design may selectively recruit participants who are more adherent to treatment than general patient populations.
“Although RCTs can provide the highest level of evidence, this design may selectively recruit participants who are more adherent to treatment than general patient populations.16”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974 · see citing works
The Expert Consensus Guideline Series
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 692 · see citing works
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625 · see citing works
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1× · see citing works
“These effects are as dramatic as those of many other widely accepted treatments in general medicine [1].”
BackgroundLeucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419 · see citing works
Self-citationTiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385 · see citing works
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213 · see citing works
Partial Compliance and Patient Consequences in Schizophrenia
Keith, S. J., & Kane, J. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1105 · Cited by 200 · see citing works
Self-citationByerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F. P., Carmody, T. J., Magouirk, B., & Rush, A. J. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.11.002 · Cited by 181 · see citing works
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147 · see citing works
Self-citationPerry, P. J., Lund, B. C., Sanger, T. M., & Beasley, C. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00004 · Cited by 142 · see citing works
Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08040484 · Cited by 122 · see citing works
Self-citationKobak, K. A., Kane, J., Thase, M. E., & Nierenberg, A. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802eb4b7 · Cited by 112 · see citing works
Self-citationHaddad, P. M., Taylor, M., & Niaz, O. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s20 · Cited by 97 · see citing works
Compliance in the long-term treatment of schizophrenia.
Kane, J. M., & Borenstein, M. (1985) · PubMed · Cited by 52 · see citing works
Self-citationExperiments in Social Process: A Symposium on Social Psychology
Overholser, W. (1951) · American Journal of Psychiatry · doi:10.1176/ajp.107.12.940-a · Cited by 33 · see citing works
Compliance in long-term treatment of schizophrenia
Linden, M., & Godemann, F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)88716-6 · Cited by 25 · see citing works
Experiments in Social Process; A Symposium on Social Psychology
B., M., & Miller, J. G. (1951) · The American Journal of Psychology · doi:10.2307/1419033 · Cited by 24 · see citing works
Schooler, N. R. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70019-1 · Cited by 10 · see citing works
Kishimoto, T. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70212-8 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324 · see citing works
Self-citationMasuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 321 · see citing works
Self-citationThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J. J., & Doshi, J. A. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.9.754 · Cited by 249 · see citing works
Series: Pragmatic trials and real world evidence: Paper 1. Introduction
Zuidgeest, M. G. P., GOETZ, I. A., Groenwold, R. H. H., Irving, E. A., van Thiel, G. J. M. W., & Grobbee, D. E. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.12.023 · Cited by 224 · see citing works
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 210 · see citing works
Self-citationKaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works
Self-citationCorrell, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 153 · see citing works
Self-citationEmerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers
Shigeyasu, K., Toden, S., Zumwalt, T. J., Okugawa, Y., & Goel, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1676 · Cited by 145 · see citing works
Alphs, L. D., Benson, C. J., Cheshire-Kinney, K., Lindenmayer, J., Mao, L., Rodriguez, S. C., & Starr, H. L. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09584 · Cited by 137 · see citing works
Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 116 · see citing works
Self-citationClinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109 · see citing works
The Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98 · see citing works
Self-citationTreatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 84 · see citing works
Determinants of adherence to treatment in first-episode psychosis: a comprehensive review
Leclerc, E., Noto, C., Bressan, R. A., & Brietzke, E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1539 · Cited by 78 · see citing works
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 78 · see citing works
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 78 · see citing works
Guinart, D., Misawa, F., Rubio, J. M., Pereira, J., de Filippis, R., Gastaldon, C., Kane, J. M., & Correll, C. U. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13359 · Cited by 57 · see citing works
Self-citationValue of schizophrenia treatment I: The patient journey
Mohr, P., Galderisi, S., Boyer, P., Wasserman, D., Arteel, P., Ieven, A., Kärkkäinen, H., Pereira, E., Guldemond, N., Winkler, P., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.06.007 · Cited by 54 · see citing works
Mohr, P., Knytl, P., Voráčková, V., Bravermanová, A., & Melicher, T. (2017) · International journal of clinical practice · doi:10.1111/ijcp.12997 · Cited by 43 · see citing works
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews, M., Gopal, S., Nuamah, I. F., Hargarter, L., Savitz, A. J., Kim, E., Tan, W., Soares, B. G., & Correll, C. U. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s197225 · Cited by 45 · see citing works
Self-citationSajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works
Self-citationFagiolini, A. M., Rocca, P., Giorgi, S. D., Spina, E., Amodeo, G., & Amore, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.044 · Cited by 44 · see citing works
Guinart, D., Taipale, H. T., Rubio, J. M., Tanskanen, A. J., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab062 · Cited by 43 · see citing works
Self-citationLorenzo, R. D., Ferri, P., Cameli, M., Rovesti, S., & Piemonte, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189245 · Cited by 36 · see citing works
Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies
Amato, D., Beasley, C. L., Hahn, M., & Vernon, A. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.004 · Cited by 40 · see citing works
Sajatovic, M., ROSS, R. W., Legacy, S. N., Byerly, M., Kane, J. M., DiBiasi, F., Fitzgerald, H. M., & Correll, C. U. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167485 · Cited by 38 · see citing works
Self-citationLong-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge
Ifteni, P. I., Dima, L., & Teodorescu, A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.04.030 · Cited by 39 · see citing works
Suzuki, T. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 40 · see citing works
Correll, C. U., Litman, R. E., Filts, Y., Llaudó, J., Naber, D., Torres, F., & Martínez, J. (2020) · Schizophrenia · doi:10.1038/s41537-020-00127-y · Cited by 38 · see citing works
Self-citationANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 37 · see citing works
Munday, J., Greene, M., Chang, E. Y., Hartry, A., Yan, T., & Broder, M. S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571295 · Cited by 36 · see citing works
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36 · see citing works
Self-citationBossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33 · see citing works
Self-citationOlagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 33 · see citing works
MacEwan, J. P., Kamat, S., Duffy, R. A., Seabury, S. A., Chou, J. W., Legacy, S. N., Hartry, A., Eramo, A., & Karson, C. N. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500455 · Cited by 32 · see citing works
Verdoux, H., Pambrun, É., Tournier, M., Bezin, J., & Pariente, A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12722 · Cited by 31 · see citing works
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1946-x · Cited by 30 · see citing works
Self-citationVita, G., Tavella, A., Ostuzzi, G., Tedeschi, F., Prisco, M. D., Segarra, R., Solmi, M., Barbui, C., & Correll, C. U. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241257062 · Cited by 29 · see citing works
Self-citationDecuypere, F., Sermon, J., Geerts, P., Denee, T. R., de Vos, C. D., Malfait, B., Lamotte, M., & Mulder, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179049 · Cited by 28 · see citing works
Chestnykh, D., Amato, D., Kornhuber, J., & Müller, C. P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113144 · Cited by 29 · see citing works
Correll, C. U., Sliwa, J. K., Najarian, D. M., & Saklad, S. R. (2019) · CNS Spectrums · doi:10.1017/s1092852918001098 · Cited by 27 · see citing works
Self-citationWeiser, M., Davis, J. M., Brown, C. H., Slade, E. P., Fang, L., Medoff, D. R., Buchanan, R. W., Levi, L. W., Davidson, M., & Kreyenbuhl, J. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111657 · Cited by 24 · see citing works
Correll, C. U., Benson, C. J., Émond, B., Patel, C. A., Lafeuille, M., Lin, D., Morrison, L., Ghelerter, I., Lefèbvre, P., & Mavros, P. (2023) · Schizophrenia · doi:10.1038/s41537-023-00334-3 · Cited by 25 · see citing works
Self-citationPeters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V., & Correll, C. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 25 · see citing works
Self-citationThoma, R., Chaze, C., Lewine, J., Calhoun, V., Clark, V., Bustillo, J., Houck, J., Ford, J., Bigelow, R., Wilhelmi, C., et al. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00039 · Cited by 26 · see citing works
Medrano, S., Abdel‐Baki, A., Stip, É., & Potvin, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4577 · Cited by 24 · see citing works
Lafeuille, M., Frois, C., Cloutier, M., Duh, M. S., Lefèbvre, P., Pesa, J. A., Clancy, Z., Fastenau, J. M., & Durkin, M. (2016) · Europe PMC (PubMed Central) · Cited by 22 · see citing works
Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie
Crocq, M. A. (2015) · L Encéphale · doi:10.1016/j.encep.2014.12.002 · Cited by 23 · see citing works
Riboldi, I., Cavaleri, D., Capogrosso, C. A., Crocamo, C., Bartoli, F., & Carrà, G. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s371991 · Cited by 22 · see citing works
Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia
Javitt, D. C. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0010-9 · Cited by 23 · see citing works
Girardi, P., CASALE, A. D., Rapinesi, C., Kotzalidis, G. D., Splendori, F., Verzura, C., Trovini, G., Sorice, S., Carrus, D., Mancinelli, I., et al. (2018) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2658 · Cited by 21 · see citing works
Schneeweiß, S., Seeger, J. D., Jackson, J. W., & Smith, S. R. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.05.012 · Cited by 20 · see citing works
Naber, D., Baker, R. A., Eramo, A., Forray, C., Hansen, K., Sapin, C., Peters-Strickland, T. S., Nylander, A., Hertel, P., Schmidt, S. N., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.013 · Cited by 20 · see citing works
Poloni, N., Ielmini, M., Caselli, I., Lucca, G., Gasparini, A., Gasparini, A., Lorenzoli, G., & Callegari, C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4590 · Cited by 20 · see citing works
Abdel‐Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, M. R., Stip, É., & Potvin, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000310 · Cited by 20 · see citing works
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 19 · see citing works
Self-citationMiura, G., Misawa, F., Kawade, Y., Fujii, Y., Mimura, M., & Kishimoto, T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001082 · Cited by 17 · see citing works
Self-citationPae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.434 · Cited by 18 · see citing works
Mustafa, F. A. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12699 · Cited by 17 · see citing works
Feng, Y., Si, T., Zhang, K.-R., Tang, J., Fang, M., Li, K., & Zhuo, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s81760 · Cited by 16 · see citing works
Emsley, R., Parellada, E., Bioque, M., Herrera, B., Hernando, T., & García-Dorado, M. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000195 · Cited by 17 · see citing works
Bartoli, F., Cavaleri, D., Callovini, T., Riboldi, I., Crocamo, C., D’Agostino, A., Martinotti, G., Bertolini, F., Ostuzzi, G., Barbui, C., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114405 · Cited by 15 · see citing works
Pietrini, F., Spadafora, M., Tatini, L., Talamba, G. A., Andrisano, C., Boncompagni, G., Manetti, M., Ricca, V., & Ballerini, A. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.05.008 · Cited by 15 · see citing works
Bozzatello, P., Bellino, S., Mancini, I., Sandei, L., Zanalda, E., & Rocca, P. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0734-1 · Cited by 15 · see citing works
Integrated treatment of schizophrenia
Altamura, A. C., Fagiolini, A. M., Galderisi, S., Rocca, P., & Rossi, A. (2015) · Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" · Cited by 15 · see citing works
Auxilia, A. M., Buoli, M., Caldiroli, A., Carnevali, G. S., Tringali, A. G. M., Nava, R., Clerici, M., & Capuzzi, E. (2023) · Biomedicines · doi:10.3390/biomedicines11020314 · Cited by 14 · see citing works
Treatment resistance and other complicating factors in the management of schizophrenia
Strassnig, M., & Harvey, P. D. (2014) · CNS Spectrums · doi:10.1017/s1092852914000571 · Cited by 14 · see citing works
Guidelines for the use of second-generation long-acting antipsychotics
Jarema, M., Wichniak, A., Dudek, D., Samochowiec, J., Bieńkowski, P., & RYBAKOWSKI, J. K. (2015) · Psychiatria Polska · doi:10.12740/pp/39370 · Cited by 14 · see citing works
The polygenic basis of relapse after a first episode of schizophrenia.
Segura, À., Prohens, L., Gassó, P., Rodríguez, N., García-Rizo, C., Moreno-Izco, L., Andreu-Bernabeu, Á., Zorrilla, I., Mané, A., Rodríguez-Jiménez, R., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.06.003 · Cited by 14 · see citing works
Chen, W. J., Liu, C., Liu, C.-C., Kuo, P., Chan, H., Lin, Y., Chung, Y.-C. E., & Chen, W. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17006 · Cited by 13 · see citing works
The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia
Kahn, R. S., & Giannopoulou, A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1070670 · Cited by 13 · see citing works
Morrato, E. H., Parks, J., Campagna, E. J., Muser, E., Thomas, D. S. K., Fang, H., & Doshi, D. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.50 · Cited by 13 · see citing works
Oya, K., Kishi, T., & Iwata, N. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91397 · Cited by 13 · see citing works
Litman, R. E., Naber, D., Anta, L., Martínez, J., Filts, Y., & Correll, C. U. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s392351 · Cited by 12 · see citing works
Self-citationCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
Carpiniello, B., & Pinna, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s86301 · Cited by 12 · see citing works
Correll, C. U., Brieden, A., & Janetzky, W. (2023) · Schizophrenia · doi:10.1038/s41537-023-00405-5 · Cited by 14 · see citing works
Self-citationPatel, R., Brinn, A., Irving, J., Chaturvedi, J., Gudiseva, S., Correll, C. U., Fusar‐Poli, P., & McGuire, P. K. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231211575 · Cited by 11 · see citing works
Self-citationCompulsory community treatment: beyond randomised controlled trials
Mustafa, F. A. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30420-6 · Cited by 11 · see citing works
Vgontzas, A. N., Paschalidou, A., Simos, P. G., Anastasaki, M., Zografaki, A., Volikos, E., Koutra, K., & Basta, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115676 · Cited by 10 · see citing works
Correll, C. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 10 · see citing works
Self-citationTreatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation
Rittmannsberger, H., Rosenleitner, J., Malsiner‐Walli, G., Werl, R., Rittmannsberger, B., & Yazdi, K. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000672 · Cited by 10 · see citing works
Jackson, J. W., Fulchino, L. A., Rogers, J. R., Mogun, H., Polinski, J. M., Henderson, D., Schneeweiss, S., & Fischer, M. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4354 · Cited by 11 · see citing works
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri, T. J., Mican, L. M., Rozea, H., & Barner, J. C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4571 · Cited by 10 · see citing works
Fusar-Poli, P., Pillinger, T., McCutcheon, R., Rangaswamy, T., Asmal, L., Singh, S. P., Oliver, D., Stefanelli, R., Crossley, N. A., Gadelha, A., et al. (2026) · World Psychiatry · doi:10.1002/wps.70066 · Cited by 10 · see citing works
Self-citationMontemagni, C., Favero, E. D., Cocuzza, E., Vischia, F., & Rocca, P. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221122526 · Cited by 10 · see citing works
Adamus, C., Zürcher, S. J., & Richter, D. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04133-5 · Cited by 8 · see citing works
Yoshimatsu, K., Elser, A., Thomas, M., Dilley, J., Barnes, D. E., Ballinger, A. L., Wozniak, S., & Mangurian, C. V. (2019) · Community Mental Health Journal · doi:10.1007/s10597-019-00412-w · Cited by 8 · see citing works
Levitan, B. S., Markowitz, M., Turkoz, I., Fu, D., Gopal, S., & Alphs, L. D. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000141 · Cited by 8 · see citing works
Efficacy of LAI in first episode psychosis: an observational study--clinical reports.
Cervone, A., D’Onghia, A., Ferrara, M., & Massaro, C. R. M. (2015) · PubMed · Cited by 7 · see citing works
Switching away from pipotiazine palmitate: a naturalistic study
Mustafa, F. A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316672575 · Cited by 7 · see citing works
Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review
Etienne, M., & Verdoux, H. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.002 · Cited by 6 · see citing works
Bardi, F., Moccia, L., Kotzalidis, G. D., Boggio, G., Brugnami, A., Sfratta, G., Janiri, D., Sani, G., & Simonetti, A. (2025) · Healthcare · doi:10.3390/healthcare13141709 · Cited by 6 · see citing works
Cameron, C. G., Zummo, J., Desai, D. N., Drake, C., Hutton, B., Kotb, A., & Weiden, P. J. (2017) · Value in Health · doi:10.1016/j.jval.2017.03.010 · Cited by 6 · see citing works
Meyer, A., Truman, K. A., Totlani, J., William, C., Brown, H., Shah, S. R., Hirsch, D., Salem, M., Chang, T., Abdelsalam, R., et al. (2024) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174241310091 · Cited by 5 · see citing works
RetractedCarmassi, C., Milani, F., Bertelloni, C. A., Massimetti, E., Cerù, A., & Dell’Osso, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13787 · Cited by 5 · see citing works
Zhang, Q., Zhong, F., Wu, M., & Zhang, X. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1299-8 · Cited by 5 · see citing works
Brasso, C., Beoni, A. M., Colli, G., Mariani, G. N., & Rocca, P. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251367591 · Cited by 4 · see citing works
Cirnigliaro, G., Battini, V., Cafaro, R., Mosini, G., Vanzetto, S., Prodi, T., Macellaro, M., Leuzzi, R., Conti, D., Carnovale, C., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2263650 · Cited by 4 · see citing works
- Authors
- Kane, J. M., Kishimoto, T., & Correll, C. U.
- Affiliations
- Albert Einstein College of Medicine (US)
- Northwell Health (US)
- Corresponding author
- Kane, John M.
- Venue
- Journal of Clinical Epidemiology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 66
- Issue
- 8
- Pages
- S37-S41
- ISSN
- 0895-4356 (ISSN-L)
- PMC
- PMC3742035
- OpenAlex
- W2012479321
- Semantic Scholar
- 953666f6c829e3913f6fe5f7aced501c8c2e2dc1
- Cited by
- 131
- References
- 20
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 14 · 2018: 12 · 2017: 15 · 2016: 14 · 2015: 17 · 2014: 8 · 2013: 2
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Epidemiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (P30MH074543, P30MH060575, P30MH090590)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- long-acting injectable antipsychotics, oral antipsychotics, relapse prevention, schizophrenia, medication adherence, randomized controlled trials, mirror-image study, cohort studies, comparative effectiveness research
- MeSH terms
- Assessment of Medication Adherence, Delayed-Action Preparations, Humans, Injections, Intramuscular, Psychiatry, Research Design, Schizophrenia, Antipsychotic Agents, Cohort Studies, Bias, Randomized Controlled Trials as Topic, Treatment Outcome, Drug Monitoring, Patient Selection, Medication Adherence, Secondary Prevention, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
